There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
1 response
1,314 views
0 reactions
|
06-18-2018, 11:55 PM
|
|||
|
3 responses
2,587 views
0 reactions
|
by Meyana
06-18-2018, 05:54 PM
|
|||
|
0 responses
1,192 views
0 reactions
|
by SuzuBell
06-18-2018, 01:44 PM
|
|||
|
5 responses
5,055 views
0 reactions
|
by JBKri
06-14-2018, 03:46 AM
|
|||
|
5 responses
2,267 views
0 reactions
|
by RickC7
06-13-2018, 10:14 AM
|
|||
|
1 response
2,876 views
0 reactions
|
by psreddy
06-09-2018, 12:42 AM
|
|||
|
12 responses
3,868 views
0 reactions
|
by pmiguel
06-08-2018, 04:11 AM
|
|||
|
3 responses
1,739 views
0 reactions
|
by ATϟGC
06-04-2018, 11:34 AM
|
|||
|
1 response
3,010 views
0 reactions
|
06-01-2018, 01:15 PM
|
|||
|
1 response
2,832 views
0 reactions
|
by finswimmer
05-30-2018, 08:00 PM
|
No topics found.
-
Next-generation sequencing (NGS) is now central to outbreak investigations and antimicrobial resistance tracking. Through sophisticated...07-31-2026, 07:00 AM
-
The immune system’s power comes from its genetic diversity, allowing myriad threats to be neutralized through first recognizing foreign antigens. That diversity is also what makes the immune system so difficult to study. Recent advances in sequencing technology and computational biology, however, are giving researchers new tools to understand immune responses and immune-related diseases in greater detail.
This convergence of genetics, immunology, and computation...09-01-2026, 05:41 AM -
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM
